Scribd Logo
Upload

Welcome to Scribd!

  • Patents

    Uploaded by

    veronicazhang911
    3 views1 page
    Two phase III clinical trials, CONFIRM and FALCON, evaluated the efficacy of fulvestrant as a second-line endocrine therapy in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. CONFIRM showed improved progression-free survival of 6.5 months versus 5.5 months and overall survival of 26.4 months versus 22.3 months for fulvestrant compared to an aromatase inhibitor. FALCON demonstrated longer progression-free survival of 16.6 months versus 13.8 months for fulvestrant versus an aromatase inhibitor. The document also provides patent expiration dates for the CDK 4/6 inhibitors palbociclib, ribocic

    Original Description:

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Two phase III clinical trials, CONFIRM and FALCON, evaluated the efficacy of fulvestrant as a second-line endocrine therapy in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. CONFIRM showed improved progression-free survival of 6.5 months versus 5.5 months and overall survival of 26.4 months versus 22.3 months for fulvestrant compared to an aromatase inhibitor. FALCON demonstrated longer progression-free survival of 16.6 months versus 13.8 months for fulvestrant versus an aromatase inhibitor. The document also provides patent expiration dates for the CDK 4/6 inhibitors palbociclib, ribocic

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    3 views1 page

    Patents

    Uploaded by

    veronicazhang911
    Two phase III clinical trials, CONFIRM and FALCON, evaluated the efficacy of fulvestrant as a second-line endocrine therapy in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. CONFIRM showed improved progression-free survival of 6.5 months versus 5.5 months and overall survival of 26.4 months versus 22.3 months for fulvestrant compared to an aromatase inhibitor. FALCON demonstrated longer progression-free survival of 16.6 months versus 13.8 months for fulvestrant versus an aromatase inhibitor. The document also provides patent expiration dates for the CDK 4/6 inhibitors palbociclib, ribocic

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    Single-agent Fulvestrant for Second-line Therapy

    Study CONFIRM FALCON


    Name
    Phase III III
    PFS 6.5 v 5.5 months (p = 16.6 v 13.8 months (p =
    0.006) 0.0486)
    OS 26.4 v 22.3 months (p = Not reported yet
    0.02)
    Link https:// https://
    www.ncbi.nlm.nih.gov/ pubmed.ncbi.nlm.nih.gov/
    pmc/articles/ 27908454/
    PMC3906991/
    Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502950/

    Palbociclib (Pfizer)
     The patent for IBRANCE (palbociclib) will expire after March 5, 2027.
    Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-
    confirms-us-patent-term-extension-ibrancer

    Ribociclib (Novartis)
     The patent for Ribociclib tablet will expire on April 14, 2036.
    Source: https://www.drugs.com/availability/generic-kisqali.html

    Abemaciclib (Eli Lilly and Company)


     The patent for Abemaciclib expires on December 15, 2029.
    Source: https://www.pharmacompass.com/patent-expiry-expiration/abemaciclib

    You might also like